Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | CCKAR | P32238 | 5/20 | 0.37 |
| ▸ | CCKBR | P32239 | 5/20 | 0.37 |
| ▸ | ITGAV | P06756 | 2/20 | 0.36 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12673961 | 1.00 | GLP1R (0.53) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL19243827 | 1.00 | GLP1R (0.53) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL12673959 | 1.00 | GLP1R (0.53) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL19243826 | 0.98 | GLP1R (0.51) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL13025471 | 0.92 | GLP1R (0.53) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL12981346 | 0.91 | GLP1R (0.49) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL12981372 | 0.91 | GLP1R (0.51) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL20567468 | 0.91 | GLP1R (0.50) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL20567466 | 0.91 | GLP1R (0.50) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL15824613 | 0.91 | GLP1R (0.50) | GLP1RNOD1GLO1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2019-04-18 | — | — | US | disclosed |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | disclosed |
| US-9688737-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2017-06-27 | — | — | US | disclosed |
| US-20160193154-A1 | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| EP-2910571-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-9045560-B2 | Protease stabilized, acylated insulin analogues | NOVO NORDISK A/S (DK) | 2015-06-02 | — | — | US | disclosed |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2014-03-13 | — | — | US | disclosed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 54/4885NOD1 3835/4885GLO1 1454/4885 |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885NOD1 3929/4885GLO1 1410/4885 |
| US-20160193154-A1 | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating | IAPP, INSR, GPR119 | GLP1R 26/4885NOD1 1050/4885GLO1 1481/4885 |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885NOD1 3929/4885GLO1 1410/4885 |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 54/4885NOD1 3835/4885GLO1 1454/4885 |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885NOD1 3929/4885GLO1 1410/4885 |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | IAPP, IDE, LIPE | GLP1R 54/4885NOD1 3835/4885GLO1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.